Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.15 HKD | +0.18% |
|
+6.26% | -0.55% |
Jul. 04 | Ascentage Grants Takeda Exclusive Option for Licensing of Blood Cancer Drug | MT |
Jun. 21 | Ascentage Pharma Group Completes $75 Million Share Subscription Deal with Takeda International | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.55% | 1.07B | - | ||
+18.43% | 122B | B+ | ||
+19.81% | 112B | B+ | ||
-23.74% | 19.33B | B+ | ||
-18.45% | 16.17B | A- | ||
-19.97% | 15.6B | B | ||
-49.33% | 14.65B | A- | ||
+57.08% | 14.34B | C+ | ||
+7.95% | 14B | C+ | ||
+126.04% | 11.29B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 6855 Stock
- Ratings Ascentage Pharma Group International